| Cat.No. | Name | Information |
|---|---|---|
| M9199 | Avacopan | Avacopan (CCX168) is a first-in-class, potent, selective and orally available complement 5a receptor (C5aR1 or CD88) antagonist with an IC50 of 0.1 nM. |
| M58630 | JPE-1375 | JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice. |
| M54080 | POT-4 | POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. |
| M49822 | ANX005 | ANX005 is a monoclonal antibody that blocks the activation of the entire classical signaling pathway by inhibiting complement protein C1q, which is upstream of the complement cascade reaction, while also maintaining the functional integrity of other complement pathways. It can be used in studies related to Guillain-Barre Syndrome (GBS). |
| M31313 | Pegcetacoplan | Pegcetacoplan is a polyethylene glycolated peptide and an inhibitor of complement protein C3 that inhibits intravascular and extravascular hemolysis. |
| M30222 | PMX 205 | PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist. |
| M29607 | JR14a | JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation. |
| M25232 | Mirococept | Mirococept (APT070) is an antibody targeting to complement system C3b/C4b, as well as a membrane-localizing C3 convertase inhibitor. Mirococept reduces the release of C-peptide and pro-inflammatory cytokines, and reduces the infiltration of inflammatory cells. Mirococept reduces intraislet inflammation, which is beneficial to islet transplantation. Mirococept also inhibits increased intestinal and pulmonary vascular permeability to reduce neutrophil influx. |
| M25043 | Vilobelimab | Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc. |
| M24911 | Pozelimab | Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases. |
| M24849 | Crovalimab | Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research. |
| M21383 | Ravulizumab | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, Ravulizumab can be used for the researchs of COVID-19-associated severe pneumonia, acute lung injury and acute respiratory distress syndrome. |
| M21378 | Sutimlimab | Sutimlimab is the first inhibitor of complement protein component 1,s subcomponent (C1s) for the study of cold agglutinin syndrome, a serine protease that cleaves C4 and C2 to form C3 convertase. |
| M20998 | PMX-53 | PMX-53 is a potent CD88 (C5aR) antagonist with an IC50 of 20 nM, it inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. |
| M14076 | Iptacopan | Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. |
| M14075 | Compstatin TFA | Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. |
| M14072 | AMY-101 TFA | AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). |
| M11438 | Zilucoplan | Zilucoplan is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme into complement components C5a and C5b, and thus preventing the downstream assembly and activity of the membrane attack complex (MAC). Can be used in studies related to immune-mediated necrotizing myopathy (IMNM) and generalized myasthenia gravis (gMG). |
| M10317 | LNP023 hydrochloride (Iptacopan HCl) | Iptacopan (LNP023) hydrochloride is a first-in-class orally bioavailable, highly potent and selective complement factor B inhibitor with an IC50 value of 10 nM. |
| M10145 | Danicopan (ALXN2040) | Danicopan (ALXN2040, ACH-4471, ACH-0144471) is a first-in-class, potent, selective, orally active inhibitor of complement factor D with a Kd value of 0.54 nM for human Factor D. Danicopan can Selectively inhibits key complement factor D in the alternative pathway, blocking C3 convertase production and inhibiting alternative pathway activity. It also prevents the deposition of C3b fragments on blood erythrocytes and inhibits erythrocyte catabolism and extravascular hemolysis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
